Previous 10 | Next 10 |
-- EXPAREL average daily sales at 115% of the prior year first quarter-- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management ...
Pacira BioSciences (NASDAQ:PCRX) is scheduled to announce Q1 earnings results on Tuesday, May 4th, before market open.The consensus EPS Estimate is $0.63 (+18.9% Y/Y) and the consensus Revenue Estimate is $118.89M (+12.5% Y/Y).Over the last 2 years, PCRX has beaten EPS estimates 88% of the ti...
[[AME]], [[APO]], [[ARCB]], [[ARNC]], [[ATC]], [[BEN]], [[BEP]], [[BERY]], [[BG]], [[BHC]], [[BR]], [[CMI]], [[COP]], [[CQP]], [[CRL]], [[CRSR]], [[CTLT]], [[CVLT]], [[CVS]], [[CWH]], [[D]], [[DD]], [[DEA]], [[ETN]], [[ETRN]], [[EXPD]], [[FI]], [[FSS]], [[GCP]], [[GPN]], [[HEP]], [[HSC]], [[H...
PARSIPPANY, N.J., April 21, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on Tuesday, May 4, 2021. Following the release, the company will host a live conference cal...
Pacira BioSciences (PCRX) announces a $3.0M investment in Spine BioPharma in the form of a convertible note.The investment will support the advancement of Spine BioPharma's lead candidate, Remedisc.Remedisc is a 7-amino acid chain peptide that binds to and induces down regulation of transform...
Spine BioPharma Announces Investment by Pacira Biosciences Supports Clinical Advancement of Remedisc™ for Degenerative Disc Disease PR Newswire NEW YORK , April 20, 2021 /PRNewswire/ -- Spine BioPharma, LLC, a company committed to developing non-opiate...
-- Supports clinical advancement of lead candidate, Remedisc, for degenerative disc disease -- PARSIPPANY, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health ...
PARSIPPANY, N.J., April 14, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today filed a lawsuit against the American Society of Anesthesiologists (ASA) and various other defendants seeking pecuniary damages and the retraction of three articles that create the false an...
PARSIPPANY, N.J., April 07, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales of EXPAREL ® (bupivacaine lipo...
Pacira BioSciences (NASDAQ: PCRX) isn't a shooting star, but the company has been steadily increasing revenue and was profitable in 2020 for only the second time since its initial public offering (IPO) in 2011. The company specializes in developing presurgical and postsurgical non-o...
News, Short Squeeze, Breakout and More Instantly...
Pacira BioSciences Inc. Company Name:
PCRX Stock Symbol:
NASDAQ Market:
Pacira BioSciences Inc. Website:
TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results after the close of the U.S. markets on Tuesday July 30, 2024. Following the release, the company will host a live conference call and webc...
-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient environment – -- Rule implements the NOPAIN Act, signed into law as part of the Cons...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 86.1% to $0.514 on volume of 587,366,807 shares NVIDIA Corporation (NVDA) fell 1.3% to $122.67 on volume of 214,038,378 shares Tesla Inc. (TSLA) rose 10.2% to $231.26 on volume of 201,850,947 ...